Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension

Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension. (Credit: The U.S. Food and Drug Administration/Wikipedia.org)